Conexeu Targets $2.0bn Tissue-Restoration Gap as Lilly’s GLP-1 Market Hits $79bn
LLY•Conexeu Sciences completed its P.R.O.O.F preclinical phase targeting a tissue-restoration market set to rise from $0.7bn in 2025 to $2.0bn by 2030, driven by the GLP-1 weight-loss market’s growth from $79bn last year to a projected $190bn by 2035. Analysts project a $1,000 Eli Lilly stake could grow substantially over ten years on obesity-drug tailwinds.
1. Conexeu Completes P.R.O.O.F Preclinical Phase
Conexeu Sciences has finished its 12-month P.R.O.O.F study for CXU, validating its extracellular matrix scaffold approach for facial and body volume restoration. The company cites third-party projections that the GLP-1 weight-loss market grew to $79bn in 2025 and could reach $190bn by 2035, creating a provider economy forecast to expand from $0.7bn in 2025 to $2.0bn by 2030.
2. Long-Term Investment Outlook for Eli Lilly
Analysts highlight that Eli Lilly’s leadership in obesity drugs Foundayo and Retatrutide underpins a decade-long growth story. A model suggests a $1,000 investment today could multiply significantly over ten years, reflecting sustained demand for GLP-1 therapies and the company’s expansion in endocrinology and related treatment areas.
